1. Mahidol University's Institutional Repository (Mahidol IR)
Simple jQuery Dropdowns

Browsing by Author Thanyanan Reungwetwattana

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 22  next >
Issue DateTitleAuthor(s)
3-Aug-2019Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysisAnne Julienne Genuino; Usa Chaikledkaew; Due Ong The; Thanyanan Reungwetwattana; Ammarin Thakkinstian; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Mahidol University
1-May-2019Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 studyCaicun Zhou; Sang We Kim; Thanyanan Reungwetwattana; Jianying Zhou; Yiping Zhang; Jianxing He; Jin Ji Yang; Ying Cheng; Se Hoon Lee; Lilian Bu; Tingting Xu; Li Yang; Chao Wang; Ting Liu; Peter N. Morcos; You Lu; Li Zhang; Sun Yat-Sen University Cancer Center; Tongji University; Zhejiang Cancer Hospital; West China School of Medicine/West China Hospital of Sichuan University; Guangdong General Hospital; Asan Medical Center; SungKyunKwan University, School of Medicine; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Guangzhou Medical University; F. Hoffmann-La Roche AG; Zhejiang University; Roche Innovation Center; Jilin Cancer Hospital; Roche Pharma Development
2016ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacyPimpin Incharoen; Thanyanan Reungwetwattana; Sakditad Saowapa; Kaettipong Kamprerasart; Duangjai Pangpunyakulchai; Lalida Arsa; Artit Jinawath; Mahidol University. Faculty of Medicine Ramathibodi Hospital. Department of Pathology
1-Mar-2020Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLCWan Ling Tan; Kevin L.M. Chua; Chia Chi Lin; Victor H.F. Lee; Lye Mun Tho; Anthony W. Chan; Gwo Fuang Ho; Thanyanan Reungwetwattana; James C. Yang; Dong Wan Kim; Ross A. Soo; Yong Chan Ahn; Hiroshi Onishi; Myung Ju Ahn; Tony S.K. Mok; Daniel S.W. Tan; Fan Yang; Peking University People's Hospital; National Taiwan University Hospital; National Cancer Centre, Singapore; National University Hospital, Singapore; Seoul National University Hospital; SungKyunKwan University, School of Medicine; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; University of Malaya Medical Centre; University of Yamanashi; The University of Hong Kong; Chinese University of Hong Kong; Beacon Hospital
1-Jan-2020Association of histologic subtypes with genetic alteration and pd-l1 expression in pulmonary adenocarcinomaBantita Phruttinarakorn; Thanyanan Reungwetwattana; Pimpin Incharoen; Faculty of Medicine, Ramathibodi Hospital, Mahidol University
22-Apr-2011Chemotherapy for non-small-cell lung carcinoma: From a blanket approach to individual therapyThanyanan Reungwetwattana; Matthew J. Eadens; Julian R. Molina; Mahidol University; Mayo Medical School
20-Nov-2018CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancerThanyanan Reungwetwattana; Kazuhiko Nakagawa; Byoung Chul Cho; Manuel Cobo; Eun Kyung Cho; Alessandro Bertolini; Sabine Bohnet; Caicun Zhou; Ki Hyeong Lee; Naoyuki Nogami; Isamu Okamoto; Natasha Leighl; Rachel Hodge; Astrid McKeown; Andrew P. Brown; Yuri Rukazenkov; Suresh S. Ramalingam; Johan Vansteenkiste; Yonsei Cancer Center; Chungbuk National University Hospital; Gachon University; Tongji University; KU Leuven– University Hospital Leuven; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Universitätsklinikum Schleswig-Holstein Campus Lübeck; National Hospital Organization, Japan; Hospital Regional Universitario Carlos Haya; Kyushu University; Ontario Cancer Institute University of Toronto; AstraZeneca; Emory University School of Medicine; Kindai University; Hospital of Sondrio
21-Nov-2019Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the PhilippinesAnne Julienne Genuino; Usa Chaikledkaew; Anna Melissa Guerrero; Thanyanan Reungwetwattana; Ammarin Thakkinstian; Department of Health Manila; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Mahidol University
1-Jan-2011Current and emerging therapies in peripheral T-cell lymphoma: Focus on pralatrexateThanyanan Reungwetwattana; Sylvia Jaramillo; Julian R. Molina; Mayo Medical School; Mahidol University
1-Jan-2018Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patientsChalirmporn Atasilp; Pichai Chansriwong; Ekapob Sirachainan; Thanyanan Reungwetwattana; Apichaya Puangpetch; Santirhat Prommas; Suwannee Sirilerttrakul; Budsaba Rerkarmnuaychoke; Sansanee Wongwaisayawan; Chonlaphat Sukasem; Faculty of Medicine, Ramathibodi Hospital, Mahidol University
1-Jan-2020Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessmentAnne Julienne Genuino; Mac Ardy Junio Gloria; Usa Chaikledkaew; Thanyanan Reungwetwattana; Ammarin Thakkinstian; University of the Philippines Manila; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Mahidol University
1-Dec-2020Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapyChalirmporn Atasilp; Phichai Chansriwong; Ekaphop Sirachainan; Thanyanan Reungwetwattana; Suwannee Sirilerttrakul; Monpat Chamnanphon; Apichaya Puangpetch; Chonlaphat Sukasem; Chulalongkorn University; Rangsit University; Faculty of Medicine, Ramathibodi Hospital, Mahidol University
1-Jan-2020An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLCViola W. Zhu; Yen Ting Lin; Dong Wan Kim; Herbert H. Loong; Misako Nagasaka; Hao To; Yvonne Li En Ang; Chan Young Ock; Nishan Tchekmedyian; Sai Hong Ignatius Ou; Nicholas L. Syn; Thanyanan Reungwetwattana; Chia Chi Lin; Ross A. Soo; National Taiwan University Hospital; Yong Loo Lin School of Medicine; National Taiwan University College of Medicine; Seoul National University Hospital; Wayne State University School of Medicine; National University of Singapore; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; UCI School of Medicine; University of Nevada School of Medicine; Chinese University of Hong Kong; Pacific Shores Medical Group
1-Nov-2020Lung Cancer in ThailandThanyanan Reungwetwattana; Songporn Oranratnachai; Putipun Puataweepong; Viratch Tangsujaritvijit; Piya Cherntanomwong; Faculty of Medicine, Ramathibodi Hospital, Mahidol University
1-Jan-2015MET exon 14 deletion (METex14): Finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approvalThanyanan Reungwetwattana; Sai Hong Ignatius Ou; Mahidol University; UCI School of Medicine
1-Jul-2012Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC)Thanyanan Reungwetwattana; Saravut J. Weroha; Julian R. Molina; Mahidol University; Mayo Clinic
2-Jan-2020Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLCSuresh S. Ramalingam; Johan Vansteenkiste; David Planchard; Byoung Chul Cho; Jhanelle E. Gray; Yuichiro Ohe; Caicun Zhou; Thanyanan Reungwetwattana; Ying Cheng; Busyamas Chewaskulyong; Riyaz Shah; Manuel Cobo; Ki Hyeong Lee; Parneet Cheema; Marcello Tiseo; Thomas John; Meng Chih Lin; Fumio Imamura; Takayasu Kurata; Alexander Todd; Rachel Hodge; Matilde Saggese; Yuri Rukazenkov; Jean Charles Soria; Yonsei Cancer Center; Jilin Provincial Cancer Hospital; Shanghai Pulmonary Hospital; Chang Gung University College of Medicine; KU Leuven– University Hospital Leuven; Institut de Cancerologie Gustave Roussy; Kansai Medical University; Université Paris-Sud; National Cancer Center Hospital; University of Toronto; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Hospital Regional Universitario Carlos Haya; Università degli Studi di Parma, Facoltà di Medicina e Chirurgia; Chungbuk National University, College of Medicine; Austin Health; Moffitt Cancer Center; Maidstone Hospital; AstraZeneca; Emory University School of Medicine; Chiang Mai University; Osaka International Cancer Institute
1-Jan-2015A phase i study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumorsNuttapong Ngamphaiboon; Grace K. Dy; Wen Wee Ma; Yujie Zhao; Thanyanan Reungwetwattana; Dawn Depaolo; Yi Ding; William Brady; Gerald Fetterly; Alex A. Adjei; Roswell Park Cancer Institute; Mahidol University
20-Jan-2018Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinomaMilind Javle; Maeve Lowery; Rachna T. Shroff; Karl Heinz Weiss; Christoph Springfeld; Mitesh J. Borad; Ramesh K. Ramanathan; Lipika Goyal; Saeed Sadeghi; Teresa Macarulla; Anthony El-Khoueiry; Robin Kate Kelley; Ivan Borbath; Su Pin Choo; Do Youn Oh; Philip A. Philip; Li Tzong Chen; Thanyanan Reungwetwattana; Eric Van Cutsem; Kun Huei Yeh; Kristen Ciombor; Richard S. Finn; Anuradha Patel; Suman Sen; Dale Porter; Randi Isaacs; Andrew X. Zhu; Ghassan K. Abou-Alfa; Tanios Bekaii-Saab; National Cheng Kung University Hospital; Barbara Ann Karmanos Cancer Institute; National Cancer Centre, Singapore; KU Leuven– University Hospital Leuven; UCSF Helen Diller Family Comprehensive Cancer Center; Mayo Clinic Scottsdale-Phoenix, Arizona; National Taiwan University College of Medicine; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Keck School of Medicine of USC; University of Texas MD Anderson Cancer Center; Seoul National University; Cliniques Universitaires Saint-Luc, Brussels; Hospital Universitari Vall d'Hebron; Memorial Sloan-Kettering Cancer Center; David Geffen School of Medicine at UCLA; Ohio State University; Universitätsklinikum Heidelberg; Massachusetts General Hospital Cancer Center; Novartis Pharmaceuticals Corporation
1-May-2018Progress in the Management of Malignant Pleural Mesothelioma in 2017Amanda J. McCambridge; Andrea Napolitano; Aaron S. Mansfield; Dean A. Fennell; Yoshitaka Sekido; Anna K. Nowak; Thanyanan Reungwetwattana; Weimin Mao; Harvey I. Pass; Michele Carbone; Haining Yang; Tobias Peikert; Zhejiang Cancer Hospital; University of Leicester; Università degli Studi di Roma La Sapienza; NYU Langone Medical Center; University of Western Australia; Aichi Cancer Center Hospital and Research Institute; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; University of Hawaii at Manoa; Mayo Clinic; Zhejiang Key Laboratory of Diagnosis and Treatment Technology of Thoracic Oncology
Showing results 1 to 20 of 22  next >